
    
      This protocol aims to provide long-term follow-up and continued use of research specimens of
      patients previously enrolled on gene transfer or other immunotherapy studies at the National
      Cancer Institute as well as follow-up of subjects at extramural sites receiving these agents
      as part of a multi-site trial. Subjects will undergo an annual health history for up to 15
      years.
    
  